Clinical Study
Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients
Table 2
Patient’s baseline characteristics.
| Pt | Sex | Age | PsA duration (years) | DAS28 | PASI
| HBV DNA | HBsAg | HBsAb | HBcAb | HCV Ab | ALT | Drug | Class |
Year of starting ADA |
| 1 | M | 55 | 6 | 6.1 | 0 | Neg | Neg | Pos | Pos | Neg | N | ADA | OC (PI) | 2006 | 2 | M | 70 | 3 | 6.3 | 0 | Neg | Pos | Neg | Pos | Neg | N | ADA | IC | 2007 | 3 | F | 55 | 1 | 5.5 | 26.2 | Neg | Neg | Pos | Pos | Neg | N | ADA | OC (PI) | 2007 | 4 | F | 67 | 5 | 7.0 | 31.8 | Neg | Neg | Neg | Pos | Neg | N | ADA | OC | 2008 | 5 | M | 37 | 1 | 6.8 | 14.2 | Neg | Neg | Pos | Pos | Neg | N | ADA | OC (PI) | 2008 | 6 | F | 47 | 4 | 7.2 | 0 | Neg | Neg | Pos | Pos | Neg | N | ADA | OC (PI) | 2009 | 7 | M | 62 | 2 | 6.4 | 2.8 | Neg | Neg | Pos | Pos | Neg | N | ADA | OC (PI) | 2010 | 8 | F | 35 | 2 | 6.6 | 37.0 | Neg | Neg | Pos | Pos | Neg | N | ADA | OC (PI) | 2010 |
|
|
Pt: patient; Class: classification; ADA: adalimumab; N: normal; OC: occult carrier; PI: past infection; IC: inactive carrier.
|